loading
Precedente Chiudi:
$18.38
Aprire:
$18.41
Volume 24 ore:
15,275
Relative Volume:
0.06
Capitalizzazione di mercato:
$1.00B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-17.35%
1M Prestazione:
-18.19%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
Value
$18.32
$18.83
Intervallo di 1 settimana:
Value
$17.62
$24.09
Portata 52W:
Value
$17.62
$28.09

Bicara Therapeutics Inc Stock (BCAX) Company Profile

Name
Nome
Bicara Therapeutics Inc
Name
Telefono
617-785-8308
Name
Indirizzo
245 MAIN STREET, CAMBRIDGE
Name
Dipendente
0
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
BCAX's Discussions on Twitter

Confronta BCAX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
BCAX 18.50 1.00B 0 0 0 0.00
VRTX 447.53 115.74B 10.63B -479.80M -1.35B 13.33
REGN 741.03 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.31 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.73 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.47 24.49B 3.30B -501.07M 1.03B 11.54

Bicara Therapeutics Inc Borsa (BCAX) Ultime notizie

pulisher
Nov 19, 2024

First Turn Management LLC Takes $14.32 Million Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat

Nov 19, 2024
pulisher
Nov 18, 2024

Bicara Therapeutics (NASDAQ:BCAX) Shares Gap DownWhat's Next? - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

FY2024 EPS Estimates for BCAX Cut by Cantor Fitzgerald - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

FY2024 EPS Estimates for BCAX Reduced by Cantor Fitzgerald - MarketBeat

Nov 18, 2024
pulisher
Nov 15, 2024

Bicara Therapeutics (NASDAQ:BCAX) Shares Down 6.2%Here's Why - MarketBeat

Nov 15, 2024
pulisher
Nov 13, 2024

Bicara Therapeutics Reports Strong IPO and Clinical Advancements - TipRanks

Nov 13, 2024
pulisher
Nov 12, 2024

Bicara Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 12, 2024
pulisher
Nov 12, 2024

Bicara Therapeutics: Newly Minted Upsized IPO With Positive Early Data (NASDAQ:BCAX) - Seeking Alpha

Nov 12, 2024
pulisher
Nov 12, 2024

Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times

Nov 12, 2024
pulisher
Nov 12, 2024

Bicara's $362M IPO Success Powers Cancer Drug Trial with 64% Response Rate | BCAX Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 11, 2024

Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference - The Manila Times

Nov 11, 2024
pulisher
Nov 09, 2024

Bicara Therapeutics (NASDAQ:BCAX) Rating Increased to Strong-Buy at RODMAN&RENSHAW - Defense World

Nov 09, 2024
pulisher
Nov 06, 2024

Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $43.33 Consensus Target Price from Analysts - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Bicara Therapeutics (NASDAQ:BCAX) Upgraded to "Strong-Buy" at RODMAN&RENSHAW - MarketBeat

Nov 06, 2024
pulisher
Nov 05, 2024

Bicara Therapeutics stock gets Buy rating from H.C. Wainwright on asset - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

Rodman & Renshaw Begins Coverage on Bicara Therapeutics (NASDAQ:BCAX) - MarketBeat

Nov 05, 2024
pulisher
Oct 23, 2024

Biocon Stole Licensed Cancer Biotech to Fuel Spinoff, Suit Says - Bloomberg Law

Oct 23, 2024
pulisher
Oct 21, 2024

Morgan Stanley spotlights 10 small-cap stocks with at least 50% upside - Kursiv Media

Oct 21, 2024
pulisher
Oct 18, 2024

Bicara Therapeutics (NASDAQ:BCAX) Trading Up 7.9%Should You Buy? - MarketBeat

Oct 18, 2024
pulisher
Oct 16, 2024

Balance Sheet Breakdown: Bicara Therapeutics Inc. (BCAX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex

Oct 16, 2024
pulisher
Oct 11, 2024

In the Green: Bicara Therapeutics Inc. (BCAX) Closes at 19.00, Up/Down -6.40 from Previous Day - The Dwinnex

Oct 11, 2024
pulisher
Oct 10, 2024

Bicara Therapeutics (NASDAQ:BCAX) Hits New 52-Week LowWhat's Next? - MarketBeat

Oct 10, 2024
pulisher
Oct 10, 2024

Down rounds don’t aid post-IPO performance - BioCentury

Oct 10, 2024
pulisher
Oct 08, 2024

Bicara shares initiated with Buy on cancer drug potential By Investing.com - Investing.com South Africa

Oct 08, 2024
pulisher
Oct 08, 2024

Bicara stock poised for growth with late-stage transition, Morgan Stanley optimistic - Investing.com

Oct 08, 2024
pulisher
Oct 08, 2024

Bicara Therapeutics stock sees upside with lead drug potential, says Stifel - Investing.com

Oct 08, 2024
pulisher
Oct 08, 2024

Bicara shares initiated with Buy on cancer drug potential - Investing.com India

Oct 08, 2024
pulisher
Oct 08, 2024

Cantor Fitzgerald starts Bicara Therapeutics with Overweight rating - Investing.com

Oct 08, 2024
pulisher
Oct 08, 2024

Cantor Fitzgerald starts Bicara Therapeutics with Overweight rating By Investing.com - Investing.com South Africa

Oct 08, 2024
pulisher
Oct 08, 2024

Bicara Therapeutics stock sees upside with lead drug potential, says Stifel By Investing.com - Investing.com South Africa

Oct 08, 2024
pulisher
Oct 07, 2024

Three startups aim to raise $400 mln as US biotech IPOs gain traction - Reuters

Oct 07, 2024
pulisher
Oct 04, 2024

Bicara Leads Trio of US Biotech IPOs Raising $703 Million - MSN

Oct 04, 2024
pulisher
Oct 02, 2024

Market Update: Bicara Therapeutics Inc. (BCAX) Sees Negative Movement, Closing at 24.43 - The Dwinnex

Oct 02, 2024
pulisher
Sep 27, 2024

Bicara Therapeutics, Adecoagro, and More Stocks See Action From Activist Investors - MSN

Sep 27, 2024
pulisher
Sep 27, 2024

Kiran Mazumdar-Shaw’s niece makes debut at Nasdaq as Bicara Therapeutics goes public - The Financial Express

Sep 27, 2024
pulisher
Sep 26, 2024

With IPO, have the capital and resources for clinical studies: Bicara CEO - The Economic Times

Sep 26, 2024
pulisher
Sep 25, 2024

Bicara Therapeutics Rings the Opening Bell - Nasdaq

Sep 25, 2024
pulisher
Sep 25, 2024

Bicara Therapeutics Rings the Nasdaq Stock Market Opening Bell - Nasdaq

Sep 25, 2024
pulisher
Sep 21, 2024

Biotech IPO Shares Climb in Debuts After Deals Upsized - MSN

Sep 21, 2024
pulisher
Sep 21, 2024

TPG GP A, LLC Acquires New Stake in Bicara Therapeutics Inc - GuruFocus.com

Sep 21, 2024
pulisher
Sep 19, 2024

James E. Flynn Buys 70,000 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) Stock - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Upstream Bio goes public amid spate of IPOs - The Pharma Letter

Sep 19, 2024
pulisher
Sep 18, 2024

Ra Capital Management, L.P. Purchases 1,833,000 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) Stock - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

Ra capital executives buy Bicara Therapeutics shares for $32.99m By Investing.com - Investing.com Canada

Sep 18, 2024
pulisher
Sep 18, 2024

Ra capital executives buy Bicara Therapeutics shares for $32.99m - Investing.com India

Sep 18, 2024
pulisher
Sep 18, 2024

FMR LLC Acquires New Stake in Bicara Therapeutics Inc - Yahoo Finance

Sep 18, 2024
pulisher
Sep 17, 2024

Deerfield entities buy Bicara Therapeutics shares worth $1.26m By Investing.com - Investing.com Australia

Sep 17, 2024
pulisher
Sep 17, 2024

Deerfield entities buy Bicara Therapeutics shares worth $1.26m - Investing.com

Sep 17, 2024
pulisher
Sep 17, 2024

Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity - Yahoo Finance

Sep 17, 2024

Bicara Therapeutics Inc Azioni (BCAX) Dati Finanziari

Non sono disponibili dati finanziari per Bicara Therapeutics Inc (BCAX). Controlla altri titoli per ulteriori informazioni.

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Bicara Therapeutics Inc Azioni (BCAX) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Flynn James E
Possible Members of 10% Group
Sep 17 '24
Buy
18.00
70,000
1,260,000
897,587
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):